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Background: An imbalance between cell proliferation and programmed cell death can result in tumor growth.
Although most systemic cytotoxic agents induce apoptosis in tumor cells, a high apoptotic rate in primary breast
cancer correlates with poor prognosis. The aim of this study was to investigate the incidence and the prognostic
significance of apoptotic disseminated tumor cells (DTC) in the bone marrow (BM) of breast cancer patients who
either underwent primary surgery or primary systemic chemotherapy (PST).
Methods: A total of 383 primary breast cancer patients with viable DTC in the BM were included into this study.
Eighty-five patients were initially treated with primary systemic chemotherapy whereas 298 patients underwent
surgery first. Detection of apoptotic DTC were performed by immunocytochemistry using the M30 antibody which
detects a neo-epitope expressed after caspase cleavage of cytokeratin 18 during early apoptosis. The median follow
up was 44 months (range 10–88 months).
Results: Eighty-two of 298 (27%) primary operated patients and 41 of 85 (48%) patients treated with primary
systemic systemic therapy had additional apoptotic DTC (M30 positive). In the neoadjuvant group M30-positive
patients were less likely to suffer relapse than those without apoptotic DTC (7% vs. 23% of the events, p = 0.049). In
contrast, the detection of apoptotic DTC in patients treated by primary surgery was significantly associated with
poor overall survival (5% vs. 12% of the events, p = 0.008).
Conclusions: Apoptotic DTC can be detected in breast cancer patients before and after systemic treatment. The
presence of apoptotic DTC in patients with PST may be induced by the cytotoxic agents. Thus, both spontaneous
and chemotherapy-induced apoptosis may have different prognostic significance.
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30-40% of primary breast cancer patients present with dis-
seminated tumor cells (DTC) at the time of diagnosis and
the detection of these cells in the bone marrow has been
shown to be a strong independent prognostic factor for
disease free and overall survival [1]. Furthermore, DTC
are able to survive systemic treatment and their persist-
ence is associated with a poor outcome [2]. However, not* Correspondence: tanja.fehm@googlemail.com
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unless otherwise stated.all of these patients develop distant metastatic disease dur-
ing follow-up suggesting that the majority of detected DTC
has a short half-life and not the capability to induce tumor
growth at secondary sites (“metastatic inefficiency”). Be-
yond mere detection of DTC, it is therefore important to
further characterize these cells with respect to their pheno-
type and apoptotic status [3].
Apoptosis is a strongly regulated process that occurs in
biological organisms leading to destruction of individual
cells [4,5]. The role of this programmed cell death in
oncogenesis has been intensively investigated in the past
two decades. Since the survival of genetically altered cells
results in carcinogenesis, an inadequate ratio of apoptosisal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical data for patients who underwent primary
surgery
n M30 positive DTC p-value
N = 298 (%)
Total 298 82 (27)
Menopausal status n.s.
Premenopausal 63 14 (22)
Postmenopausal 235 68 (29)
Tumor size n.s.
pT1 204 57 (28)
pT2-4 94 25 (27)
Nodal status n.s.
Negative 214 54 (25)
Positive 84 28 (33)
Histology n.s.
Ductal 226 63 (28)
Lobular 54 16 (30)
Others 18 3 (17)
Grading n.s.
I/II 268 74 (28)
III 30 8 (27)
ER status n.s.
Negative 45 12 (27)
Positive 253 70 (28)
PR status n.s.
Negative 53 11 (21)
Positive 245 71 (29)
HER2 status n.s.
Negative 232 69 (30)
Positive 52 12 (23)
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growth. This is considered to be a result of mutations in
oncogenes which are responsible for the regulation of
apoptosis, including BCL-2, C-MYC and P53 [6-8]. Para-
doxically, several studies have shown that a high ratio of
apoptotic cells in untreated primary breast cancer gener-
ally correlates with increased cell proliferation, negative
hormonal status, high grading and thus with a poor clin-
ical outcome [8-10]. Whether this phenomenon is re-
stricted to primary tumor or if it takes place in DTC
remains to date unclear.
In contrast, chemotherapeutic agents can induce apop-
tosis of tumor cells leading to disease regression. This
process can be explored in vivo in patients treated with
PST [11]. We have previously reported that PST may in-
duce apoptosis not only in primary tumor, but in DTC as
well [3].
The purpose of this study was to investigate the inci-
dence and prognostic significance of apoptotic DTC in
two different subgroups of primary breast cancer pa-
tients: 1) patients who underwent surgery first and 2)
patients treated with PST.
Methods
A total of 383 primary breast cancer patients treated be-
tween 2003 and 2009 at the Department of Obstetrics and
Gynecology, University of Tuebingen, Germany were en-
rolled in this study, which was approved by the local re-
search ethics committee (560/2012R). Inclusion criteria
were: non metastatic breast cancer (T1-T3, N0-3, M0) and
DTC positive BM status. Patients were subdivided into
two groups based on their treatment schedule: (1) patients
with surgery followed by adjuvant treatment (n = 298), and
(2) patients with PST (n = 85). The clinical characteristics
of patients are presented in Tables 1 and 2. The clinical re-
sponse to PST was assessed by ultrasound, mammography
and physical examination and was defined according to
the World Health Organization criteria [12]. Pathological
complete response was considered in patients with absence
of invasive tumor in the breast and negative lymph node
status. BM aspiration was performed intraoperatively in
both groups.
Collection and analysis of BM
Between 10 and 20 ml of BM were aspirated from the an-
terior iliac crest and processed within 24 hours. All speci-
mens were obtained after written informed consent from
patients. BM samples were separated by density centrifuga-
tion over Ficoll (Biochrom, Germany) with a density of
1,077 g/ml. 106 mononuclear cells were spun onto a glass
slide using a cytocentrifuge (Hettich, Tuttlingen, Germany).
Slides were than fixed in a 4% neutral buffered formalin so-
lution for 10 minutes and were rinsed in phosphate-
buffered saline. Automatic immunostaining was performedon the DAKO autostainer using the monoclonal mouse
A45–B/B3 antibody (Micromet, Munich, Germany),
and the DAKO-APAAP detection kit (DakoCytomation,
Glostrup, Denmark) according to the manufacturers’ in-
structions. For each patient, 2 × 106 cells were analyzed.
Slides were automatically scanned using the ACIS™ im-
aging system (ChromaVision, Medical Systems Inc., San
Juan, Capistrano, CA, USA) and evaluated based on the
recommendations for standardized tumor cell detection
and the criteria of the European ISHAGE Working
group [13,14]. The MCF-7 cell line served as a positive
control. Leukocytes from healthy volunteers were used
as a negative control. All BM specimens were evaluated
qualitatively, as positive and negative for DTC.
383 primary breast cancer patients with A45-B/B3
positive DTC in BM were included into this study. In
order to evaluate the apoptotic status of DTC in this
Table 2 Clinical data for patients who underwent
neoadjuvant therapy
n M30 positive DTC p-value
N = 85 (%)
Total 85 41 (48)
Menopausal status n.s.
Premenopausal 48 20 (42)
Postmenopausal 37 21 (57)
Tumor size n.s.
ypT0 19 12 (63)
ypT1 31 13 (42)
ypT2-4 35 16 (46)
Nodal status 0.007
ypN negative 39 25 (64)
ypN positive 46 16 (35)
Histology n.s.
Ductal 66 32 (49)
Lobular 15 7 (47)
Others 4 2 (50)
Grading n.s.
I/II 67 34 (50)
III 18 7 (39)
ER status n.s.
Negative 28 15 (54)
Positive 57 26 (46)
PR status n.s.
Negative 27 17 (63)
Positive 58 24 (41)
HER2 status n.s.
Negative 66 31 (47)
Positive 19 10 (53)
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antibody (Roche Applied Science, Mannheim, Germany)
and analyzed by use of the APAAP kit detection method
as described above. The M30 antibody reacts with a neo-
epitope expressed only after caspase cleavage of cytokera-
tin 18 during early apoptosis [15]. M30 antibody does not
bind intact, full-length cytokeratin 18 in viable or necrotic
cells and can, therefore, be used specifically to recognize
apoptotic cells [16]. Identification of apoptotic DTC was
based on positive M30 staining and cytomorphological cri-
teria as described elsewhere [17-19]. MCF-7 cells treated
with sodium azide served as a positive control; untreated
MCF-7 cell line and leukocytes from healthy volunteers
were used as a negative control. Figures 1 and 2 show
M30 and pan-cytokeratin staining.Statistical analysis
The chi-squared test was used to evaluate the association
between apoptotic DTC and clinicopathological factors.
Statistical analysis was performed by SPSS (version 19).
Values of p < 0.05 were considered statistically significant.
Survival intervals were measured from the time of BM bi-
opsy until death or the first diagnosis of relapse. Relapse
was defined as either local recurrence or distant metasta-
sis. Survival was calculated using Kaplan-Meier method
and compared by the log-rank test.Results
Patients characteristics
A total of 383 DTC positive breast cancer patients were
included in this study. Two-hundred ninety-eight patients
underwent breast surgery first. 204 out of 298 patients
(68%) had T1 tumors and 214 (71%) were node negative.
The most common histological tumor type was invasive
ductal carcinoma. Estrogen and progesterone receptor
status were positive in 85% and 82% of these patients, re-
spectively. Fifty-two of 284 (18%) patients had HER2 posi-
tive tumors. Clinical data of this group are summarized in
Table 1. Eighty-five patients were treated with PST. The
majority of these patients was premenopausal (48 of 85
cases). 22% achieved pathological complete response after
chemotherapy while 53% responded partially. Stable dis-
ease was observed in 19% of patients whereas 6% of pa-
tients (5 cases) developed progressive disease (Table 3).
Clinical data of patients treated with PST are summarized
in Table 2.
Presence of apoptotic DTC in patients treated with
primary surgery
In eighty-two of 298 (27%) patients with pan-cytokeratin
positive DTC in BM who underwent primary surgery
additional apoptotic DTC could be detected. No correl-
ation could be found between positive M30 status and
any established prognostic factors, including tumor size,
lymph node status, hormone receptor status or grading.Presence of apoptotic DTC in patients treated with PST
Forty-one of 85 (48%) patients had additional M30 positive
DTC after completion of PST. Patients with apoptotic DTC
were less likely to have nodal metastasis (35% vs. 64%; p =
0.007). No significant correlation could be observed be-
tween the positive M30 status of DTC and other clinico-
pathological factors. The presence of apoptotic DTC was
associated with response to PST. M30 positive cells were
found in 63% of patients with complete remission, 53%
with partial remission and 31% with stable disease, respect-
ively. None of the patients with progressive disease had
M30 positive DTC (p = 0.034; Table 3).
Figure 1 M30 control stainings (A) Cluster of M30 positive apoptotic MCF-7 cells with leukocytes in the background (positive control)
(B) Leukocytes from healthy volunteers (negative control) (C) Cluster of M30 negative viable MCF-7 cells with leukocytes in the
background (negative control).
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The median follow-up was 44 months (range: 10–88
months). 32 of 383 patients were diagnosed with relapse
(either local recurrence or distant metastasis) and 28 died
during follow-up. Clinical outcome data are summarized
in Table 4.
Survival analysis of neoadjuvant patients
Thirteen of 85 neoadjuvant patients (15%) presented
with relapse during follow-up. Patients with additional
M30 positive DTC were less likely to suffer from relapse
than patients with only non-apoptotic DTC (7% vs. 23%;
p = 0.049). However, the association between disease-free
interval and M30 status of DTC assessed by Kaplan-Meier
analysis did not reach statistical significance (p = 0.128;
70 months, 95% CI: 63–78 months vs. 81 months, 95% CI:
74–87 months). Seven of 85 neoadjuvant patients (8%)
died during follow-up. No correlation could be found be-
tween M30 status of DTC and overall survival in this
group of patients.
Survival analysis of patients treated with primary surgery
Twenty-one out of 298 (7%) patients in this group died
during follow-up. The overall survival was significantlyFigure 2 Pan-cytokeratin and M30 staining of DTC from primary breast
breast cancer patient (B) M30 positive apoptotic DTC from a primary breast c
(positive cytokeratin-staining, large nucleus, high nuclear to cytoplasmic ratio,shorter among patients with M30 positive DTC as com-
pared to M30 negative patients (75 months, 95% CI: 68–
81 months vs. 84 months, 95% CI: 81–86 months; p =
0.008). However, there was no association between dis-
ease free survival and M30 status (83 months in M30
positive patients, 95% CI: 80–85 months vs. 78 months
in M30 negative patients, 95% CI: 73–84 months; p >
0.05). Figure 3 shows the Kaplan-Meier analysis of over-
all survival in patients who underwent primary surgery.
Discussion
The presence of DTC in BM of patients with primary breast
cancer is an independent prognostic factor associated with
poor clinical outcome [1]. Although this phenomenon can
be seen in 30-40% of breast cancer patients, only a minority
of DTC positive patients will develop distant metastasis in
course of disease (“metastatic inefficiency”).
The aim of the present study was to evaluate the inci-
dence and prognostic relevance of apoptotic DTC in
breast cancer patients. We focused on two subsets of pa-
tients: 1) untreated patients whose bone marrow status
was assessed at the time of primary surgery, and 2) pre-
treated patients after completion of neoadjuvant cyto-
toxic therapy.cancer patients. (A) A45–B/B3 positive viable DTC from a primary
ancer patient. The typical morphology of a tumor cell can be recognized
nucleus partially covered by cytokeratin staining, nucleus granular).
Table 3 Apoptotic DTC and clinical response to
neoadjuvant chemotherapy
N (%) M30 positive DTC %
Total 85 (100) 41 48
Complete remission 19 (22) 12 63
Partial remission 45 (53) 24 53
Stable disease 16 (19) 5 31
Progressive disease 5 (6) 0 0
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at time of primary surgery
M30 antigen is an early apoptotic marker of epithelial
cells, detectable after caspase cleavage of cytokeratin 18.
This antibody was used in our study to assess the apop-
totic status of DTC in 298 patients who received no treat-
ment prior to surgery. Patients with apoptotic DTC had a
significantly shorter overall survival compared to patients
with only non-apoptotic DTC (75 months vs. 84 months,
p < 0.008). This seems not conclusive, since apoptotic
DTC are generally assumed to result from a phenomenon
described as “metastatic inefficiency”. According to this
conceptual model, only a small percentage of tumor cells
are able to survive and persist at secondary homing sites.
Large numbers of cancer cells are shed from the primary
site into the systemic circulation; only a small subset will
give rise to overt metastases. To successfully reach and
colonize a secondary site, a tumor cell must complete a
series of steps (metastatic cascade): migration from the
primary tumor, intravasation into the blood stream, sur-
vival of the vigorous passage in blood, extravasation, and
development of micrometastases in distant organs [20].







M30 positive 10/82 (12%) 4/41 (10%)
M30 negative 11/216 (5%) 3/44 (7%)
P 0.032 n.s.
Overall survival*
(M30 positive vs M30 negative) 0.008 n.s.
Relapses† 19 13
M30 positive 7/82 (9%) 3/41 (7%)
M30 negative 12/216 (6%) 10/44 (23%)
P n.s. 0.049
Relapse free survival* n.s. 0.128
(M30 positive vs M30 negative)
*Calculated by log-rank test. † Including local recurrence and distant metastases.tumor cells; 99,9% of shed cells are thought to perish dur-
ing the process, while only a minor subpopulation attains
metastatic capacity [21]. The key regulatory points that
contribute to metastatic inefficiency remain unclear; initi-
ation of apoptosis has been assumed to be a major compo-
nent of this mechanism. Yet, in our study apoptotic status
of DTC in bone marrow in untreated patients resulted in
significantly worse survival.
In the past decades, major research efforts have been
conducted to study the role of apoptosis in the primary
tumor [10,22]. The association between apoptosis rates
and cell proliferation is well established; increased apop-
tosis reflects a high cell turnover in the tumor. In breast
cancer, high levels of apoptosis correlate with enhanced
cellular proliferation and biological markers of increased
malignancy, such as negative hormone receptor status,
high histological grade, HER2 overexpression, positive
lymph nodes, tumor aneuploidy and a decreased expres-
sion of bcl-2 protein [10,23,24]. Furthermore, high apop-
totic counts are associated with shortened disease-free
and overall survival [9,10,24]. Similar observations were
made in other solid tumors, including prostate and blad-
der cancer [25,26]. These data seem to disprove the con-
cept that the elimination of apoptosis in tumor cells is a
necessary condition for autonomous uncontrolled cancer
growth. On the contrary, an enhanced rate of spontan-
eous apoptosis in the primary tumor is an indicator of
high proliferation and negative prognostic markers.
Clinical relevance of therapy-induced apoptosis in DTC
Over the last two decades, neoadjuvant systemic therapy
(NST) has become the standard treatment strategy for lo-
cally advanced breast cancer, conducted primarily to en-
hance the possibility of breast-conserving surgery [27].
Beyond this indication NST offers the additional possibil-
ity to test in vivo the chemosensitivity of the primary
tumor [28]. The pathological response to NST is associ-
ated with favorable clinical outcome and is considered by
some as a surrogate marker for complete eradication of
micrometastatic disease. However, up to 25% of patients
who achieve complete pathological remission will suffer
relapse within five years of diagnosis, suggesting subclin-
ical persistence of isolated tumor cells beyond systemic
treatment.
We reported previously a high incidence of persistent
DTC after NST [3]. Since apoptosis is the main mechan-
ism of chemotherapy-induced disease regression [29], we
aimed to assess the apoptotic status of DTC in patients
who received neoadjuvant therapy. In 41 out of 85 (48%)
DTC positive patients additional apoptotic tumor cells
were detected after therapy. Compared to patients with
only viable DTC, patients with apoptotic DTC responded
better to therapy, reaching complete or partial remission
in 88% (vs. 64% in the M30-negative group, p = 0.034).
Figure 3 Kaplan-Meier survival analysis depending on M30 status of DTC in bone marrow of previously untreated patients (overall survival).
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cantly associated with negative nodal status after comple-
tion of neoadjuvant treatment but not with any other
clinicopathological factor. Pathological response of the pri-
mary tumor and lymph nodes metastases was therefore
reflected by changes in tumor cells in secondary sites, such
as bone marrow. Further, patients with positive M30-status
were less likely to suffer from a relapse (p = 0.049). This is
in accordance with clinical studies: patients who achieve
complete pathological response to neoadjuvant treatment
regime perform favorably with regard to overall and
disease-free survival [30]. In addition, patients converted to
node negative disease after neoadjuvant treatment have
high survival rates, despite residual tumor in the breast
[31]. These data indicate that in these patients apoptotic
tumor cells are associated with therapy response.
Conclusions
Although the observations made in primary tumors can-
not be directly extrapolated to DTC in secondary sites,
our data suggest that high level of spontaneous apop-
tosis in minimal residual disease (MRD) is an indicator
of poor prognosis. Hypothetically, if the presence of
apoptotic DTC reflects an active status of MRD; accord-
ingly, dormant (inactive) tumor cells would appear asnon-apoptotic. In contrast, therapy-induced apoptosis
of DTC was correlated to pathological response of the
tumor and may be regarded as a favorable event. Our
data demonstrate for the first time that the biological
significance of apoptotic status of DTC is contingent
on whether the apoptosis occurs spontaneously or was
induced by treatment.
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